About Us

About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dyslipidemia Market Research Report 2025-2035 | Expansion Fueled by Rising Cardiovascular Disease Burden, Lifestyle Risks, Early Diagnostics, and Preventive Health Initiatives - ResearchAndMarkets.com

By: via Business Wire

The "Dyslipidemia Market - A Global and Regional Analysis: Focus on Drug Class, Route of Administration, and Region - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering.

Dyslipidemia, characterized by abnormal levels of lipids such as cholesterol and triglycerides in the blood, significantly elevates the risk of cardiovascular diseases. Advances in lipid profiling, genetic testing, and risk assessment tools are enabling earlier and more precise diagnosis, thereby boosting demand for personalized therapeutic interventions. Statins remain the cornerstone of treatment, with newer drug classes such as PCSK9 inhibitors and RNA-based therapies gaining traction due to their efficacy in managing resistant cases.

However, challenges including patient non-compliance, side effects associated with long-term statin use, and high costs of novel therapies limit broader market penetration, especially in low and middle-income countries. Additionally, variations in treatment guidelines and healthcare infrastructure disparities complicate standardized care delivery. Nonetheless, growing government health initiatives, increased investment in cardiovascular research, and expanding awareness campaigns are driving improved screening and treatment rates.

Impact

Technological advancements in lipid diagnostics, genetic screening, and telemedicine platforms are significantly enhancing the early detection and personalized management of dyslipidemia. Innovations such as advanced lipid profiling, AI-driven risk prediction models, and wearable cardiovascular monitoring devices are improving the precision of disease assessment and treatment customization. Additionally, the integration of digital therapeutics and remote patient management is expanding access to care, particularly in underserved or rural areas, enabling continuous monitoring and better adherence to lipid-lowering therapies.

Statins hold the highest market share in the dyslipidemia market due to their proven efficacy, safety profile, and widespread clinical adoption as the first-line therapy for lowering LDL cholesterol and reducing cardiovascular risk. Extensive clinical trial evidence supports statins' ability to significantly decrease morbidity and mortality associated with dyslipidemia-related conditions, which has solidified their position as the gold standard treatment globally.

Oral administration holds the highest market share in the dyslipidemia market, primarily because the majority of lipid-lowering drugs, including statins, fibrates, niacins, bile acid resins, and omega-3 fatty acids, are formulated for oral use. Oral medications offer greater patient convenience, ease of administration, and higher compliance compared to parenteral routes.

North America holds the highest market share in the dyslipidemia market, driven by its advanced healthcare infrastructure, high prevalence of cardiovascular diseases, and widespread adoption of lipid-lowering therapies. The region benefits from strong healthcare spending, well-established reimbursement frameworks, and early access to innovative treatments such as PCSK9 inhibitors.

How can this report add value to an organization?

Product/Innovation: This report provides comprehensive insights into the current trends in dyslipidemia, helping companies identify opportunities for drug and technology development. Organizations can leverage these insights to design therapies, medications, and platforms tailored to the needs of patients suffering from dyslipidemia, improving outcomes and enhancing market penetration.

Competitive: A detailed competitive landscape analysis helps organizations benchmark their market standing against key players. By understanding the strengths and weaknesses of competitors, companies can position themselves more effectively in the global dyslipidemia market.

Demand Drivers and Limitations

Drivers for the Global Dyslipidemia Market:

  • Increasing cases of heart disease and stroke worldwide drive demand for effective lipid-lowering treatments.
  • Lifestyle changes leading to obesity and diabetes contribute to higher dyslipidemia rates, boosting market growth
  • Improved lipid profiling and genetic testing facilitate early diagnosis, increasing treatment uptake
  • Public health initiatives promote regular cholesterol screening, leading to earlier intervention and therapy adoption

Limitations for the Global Dyslipidemia Market:

  • Long-term medication adherence is often poor due to side effects and lack of symptom awareness, limiting treatment effectiveness
  • Expensive drugs such as PCSK9 inhibitors restrict accessibility, especially in low- and middle-income countries.
  • Adverse effects such as muscle pain and liver issues lead to discontinuation or reluctance in therapy initiation.

Key Market Players

  • Amgen Inc.
  • Sanofi S.A.
  • Regeneron Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Novartis AG
  • Viatris Inc.
  • AbbVie Inc.
  • AstraZeneca plc
  • Horizon Therapeutics plc
  • Esperion Therapeutics, Inc.

Key Topics Covered:

1. Global Dyslipidemia Market: Industry Analysis

  • 1.1 Market Overview and Ecosystem
  • 1.2 Epidemiological Analysis
  • 1.3 Key Market Trends
  • 1.3.1 Impact Analysis
  • 1.4 Regulatory Landscape
  • 1.5 Pipeline Analysis
  • 1.6 Market Dynamics
  • 1.6.1 Overview
  • 1.6.2 Market Drivers
  • 1.6.3 Market Restraints
  • 1.6.4 Market Opportunities

2. Global Dyslipidemia Market (by Drug Class), Value ($million), 2023-2035

  • 2.1 Statins
  • 2.2 Bile Acid Resins
  • 2.3 Fibrates
  • 2.4 Niacins
  • 2.5 Omega-3 Fatty Acids
  • 2.6 Others

3. Global Dyslipidemia Market (by Route of Administration), Value ($million), 2023-2035

  • 3.1 Oral
  • 3.2 Parenteral

4. Global Dyslipidemia Market (by Region), Value ($Million), 2023-2035

  • 4.1 North America
  • 4.1.1 Market Dynamics
  • 4.1.2 Market Sizing and Forecast
  • 4.1.3 North America Dyslipidemia Market, by Country ($Million), 2023-2035
  • 4.1.3.1 U.S.
  • 4.1.3.2 Canada
  • 4.2 Europe
  • 4.2.1 Market Dynamics
  • 4.2.2 Market Sizing and Forecast
  • 4.2.3 Europe Dyslipidemia Market, by Country ($Million), 2023-2035
  • 4.2.3.1 U.K.
  • 4.2.3.2 France
  • 4.2.3.3 Germany
  • 4.2.3.4 Italy
  • 4.2.3.5 Spain
  • 4.2.3.6 Rest-of-Europe
  • 4.3 Asia-Pacific
  • 4.3.1 Market Dynamics
  • 4.3.2 Market Sizing and Forecast
  • 4.3.3 Asia-Pacific Dyslipidemia Market, by Country ($Million), 2023-2035
  • 4.3.3.1 Japan
  • 4.3.3.2 China
  • 4.3.3.3 India
  • 4.3.3.4 Australia
  • 4.3.3.5 South Korea
  • 4.3.3.6 Rest-of-Asia-Pacific
  • 4.4 Rest-of-the-World
  • 4.4.1 Market Dynamics
  • 4.4.2 Market Sizing and Forecast Rest-of-the-World Dyslipidemia Market, by Type ($Million), 2023-2035
  • 4.4.3 Rest-of-the-World Dyslipidemia Disorder Market, by Country ($Million), 2023-2035
  • 4.4.3.1 Latin America
  • 4.4.3.2 Middle East and Africa

5. Competitive Landscape and Company Profiles

  • 5.1 Competitive Landscape
  • 5.1.1 Mergers and Acquisitions
  • 5.1.2 Partnership, Alliances and Business Expansion
  • 5.1.3 New Offerings
  • 5.1.4 Regulatory Activities
  • 5.1.5 Funding Activities
  • 5.2 Company Profiles
  • 5.2.1 Overview
  • 5.2.2 Top Products / Product Portfolio
  • 5.2.3 Top Competitors
  • 5.2.4 Target Customers/End-Users
  • 5.2.5 Key Personnel
  • 5.2.6 Analyst View

6. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/htp9qf

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

More News

View More
Cybersecurity Market Set to Double: This ETF Offers Exposure
Via MarketBeat
Topics Artificial Intelligence Credit Cards ETFs
Tickers BUG CRWD CYBR PANW VRNS ZS
Downgraded But Not Done: 3 Stocks Ready for a Market Comeback
Via MarketBeat
Topics Artificial Intelligence
Tickers CRM CRWD FTNT
Solana Beat BTC and ETH in Q3: These 3 Stocks Saw It Coming
Via MarketBeat
Topics ETFs
Tickers DFDV F FORD JNVR MSTR UPXI
Ford Set to Outpace GM With Tariff Tailwinds and EPS Momentum
Via MarketBeat
Topics World Trade
Tickers F GM TSLA
Replace Your Fixed Income With This Dividend ETF
Via MarketBeat
Topics ETFs Economy
Tickers AMZN JEPI META NVDA
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.